Filing Flows › Decoy Therapeutics (DCOY) › Q2 2026
Decoy Therapeutics (DCOY) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Decoy Therapeutics (DCOY) reported revenue of $228K for the second quarter 2026 (Q2 2026).
Decoy Therapeutics, Q2 2026: revenue $228K, net loss $2.4M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $228K | — | — |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$2.4M | — | — |
| Operating cash flow | −$2.7M | — | — |
What changed
Revenue was $228K in Q2 2026.
Operating costs exceeded revenue by $2.6M, an operating margin of -1155.8%. The quarter ended with a net loss of $2.4M.
Operating cash flow was −$2.7M. Non-cash charges added back $14K of depreciation and amortization and $206K of share-based compensation. Working capital and other items used $498K.
Questions
What was Decoy Therapeutics' revenue in the second quarter 2026?
Decoy Therapeutics (DCOY) reported revenue of $228K for the second quarter 2026 (Q2 2026).
Source: Decoy Therapeutics 10-Q on SEC EDGAR.